Rocket Pharmaceuticals, Inc..
RCKT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare and devastating diseases. The company's pipeline includes programs targeting Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), and Danon ...Show More
Better Health for All
30
Rocket Pharmaceuticals is focused on developing gene therapies for rare and devastating diseases, including Danon disease, Fanconi Anemia and Leukocyte Adhesion Deficiency-I
1
,
2
,
3
. A $6.5mm grant was awarded by the California Institute for Regenerative Medicine (CIRM) to Rocket Pharmaceuticals
4
. The company is committed to ethical clinical trials, GCP, and informed consent
5
. Employee engagement initiatives include Rocket First Connections, Black History Month events, and Family and Science Night
6
. The company also promotes patient and family resources, including events (Rare Disease Day), a photo crowdsourcing initiative, and opportunities to share stories and experiences
7
. The company donated $10,000 to Make-A-Wish and $10,000 to UNICEF in 2023
8
. The company has an information security program with policies and procedures for data protection, including personal health information
9
. The company's cash, cash equivalents, and investments totaled $318.2M as of March 31, 2025, and management expects this to fund operations into Q4 2026
10
.
Fair Money & Economic Opportunity
0
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer consumer financial products or services.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity,' which are designed for financial institutions, are not applicable to Rocket Pharmaceuticals.
Fair Pay & Worker Respect
-20
Rocket Pharmaceuticals has a CEO to median employee pay ratio of 50:1, which is among industry-leading benchmarks.
1
Glassdoor reviews give the company an overall rating of 3.1 out of 5 stars, with 48% of employees recommending the company.
2
Employee ratings for compensation and benefits are at 3.0 out of 5 stars.
3
Health insurance is available to US-based employees, with a rating of 4.2 out of 5.
4
However, reviews also mention concerns about management, culture, and potential favoritism.
5
Given the mixed reviews and lack of comprehensive data on living wages, pay equity, and other key metrics, a conservative score is warranted.
6
7
8
9
10
11
12
The company's business model relies on skilled labor, making fair treatment important. The company offers medical, dental, vision, and life insurance, as well as a 401k match.
13
Fair Trade & Ethical Sourcing
0
No information regarding Rocket Pharmaceuticals, Inc.'s fair trade and ethical sourcing practices, supply chain audits, forced/child labor incidents, traceability, remediation speed, ethical clause coverage, materials risk index, or supplier diversity spend was found in the provided articles.
1
Honest & Fair Business
0
Insufficient evidence to determine a value score for Rocket Pharmaceuticals, Inc. regarding Honest & Fair Business. No articles or relevant information found. A neutral score of 0 is assigned.
Materiality Analysis: Company Summary: Rocket Pharmaceuticals is a late-stage biotechnology company focused on developing gene therapies for rare diseases. Its core activities involve research, clinical trials, and eventual commercialization of gene therapies targeting conditions like Danon disease, Fanconi Anemia, and Leukocyte Adhesion Deficiency-I. The company operates primarily in the United States, with licensing agreements involving international research institutions. Recent strategic focus is on advancing its pipeline through clinical trials.
Peer Comparison: Compared to other biotech companies, Rocket Pharmaceuticals' performance on "Honest & Fair Business" is likely at the industry standard. Biotech firms generally face high regulatory scrutiny and require transparency in clinical trial data. However, smaller companies may have less developed formal governance structures than larger peers.
Materiality Assessment: The business model is fundamentally neutral to this value, with medium materiality.
Detailed Rationale: As a biotech company, Rocket Pharmaceuticals is subject to significant regulatory oversight by agencies like the FDA. Maintaining ethical conduct in clinical trials, accurate reporting of data, and compliance with regulations are crucial. Any instances of fraud, data manipulation, or regulatory violations could severely impact the company's reputation, stock price, and ability to bring therapies to market. While the company's core business doesn't inherently promote dishonesty, the high-stakes nature of drug development and the potential for conflicts of interest necessitate strong governance and transparency. The company's licensing agreements also require fair dealing and adherence to ethical research practices.
Value Interaction Notes: N/A
Scoring Boundary Flags: Scores indicating extremely poor performance (e.g., due to major fraud or regulatory violations) would be illogical unless substantiated by concrete evidence, as this would likely trigger immediate and severe consequences for the company. A score below 3 is unlikely absent major scandal.
Kind to Animals
0
Rocket Pharmaceuticals, Inc. conducts animal testing for product development, as evidenced by a press release announcing animal study data for its RP-A501 program and its ESG profile indicating 'Animal testing Yes'.
1
However, the provided articles do not offer any specific details regarding the company's animal testing policies, the volume of animals used, the extent of non-animal testing methods employed, or any certifications related to cruelty-free practices or humane operations. There is also no information on ethical sourcing, supplier audits, or wildlife conservation initiatives. Therefore, no KPIs can be scored based on the available evidence.
No War, No Weapons
0
No evidence available to assess Rocket Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Rocket Pharmaceuticals, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
The provided articles do not contain specific, concrete data points for any of the KPIs related to 'Respect for Cultures & Communities' for Rocket Pharmaceuticals, Inc. (RCKT.US). While mentions a $10,000 donation to Make-A-Wish New Jersey and UNICEF, these are not classified as cultural heritage organizations as per the KPI definition for 'charitable_giving_cultural'.
1
Furthermore, no revenue figure for RCKT.US is provided to calculate a percentage for this or any other revenue-based KPI. discusses the Rocket Community Fund, but explicitly states it is a philanthropic partner of Rocket Companies, not RCKT.US, and its activities focus on housing and financial stability, not cultural respect.
2
Other articles provide general company information or diversity metrics (e.g., BIPOC employee base) which do not directly map to the specific KPIs for local employment ratio or indigenous engagement.
3
Safe & Smart Tech
0
Rocket Pharmaceuticals allows users to manage cookie preferences and opt-out of Google Analytics and personalized ad delivery, which represents industry-standard user data control.
1
The company's policy requires employees to collect the minimum amount of information necessary for business purposes and to store personal information only as long as needed.
2
Rocket Pharmaceuticals and its employees are required to comply with all applicable laws and regulations, including the U.S. Foreign Corrupt Practices Act, the UK Bribery Act, and trade laws.
3
The company also has a policy for full, fair, accurate, timely, and understandable disclosure in reports and documents filed with the SEC and in other public communications.
4
Zero Waste & Sustainable Products
-60
Rocket Pharmaceuticals reported recycling 665 lbs of hazardous and lab waste out of a total of 27,000 lbs of hazardous chemical and biological waste, resulting in a waste diversion rate of 2.46%.
1
The company participated in Earth Day and Earth Month events, which included diverting e-waste and batteries from landfills.
2
The company manages hazardous chemical and biological waste, with some hazardous and lab waste being recycled.